알레르기 면역요법 시장 : 유형별, 용도별, 유통 채널별 - 세계 기회 분석 및 산업 예측(2024-2033년)

Allergy Immunotherapy Market By Type , By Application By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033

US $ 4,425 ￦ 6,402,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 7,412 ￦ 10,724,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

알레르기 면역요법 시장의 2023년 시장 규모는 18억 달러로 2024-2033년 CAGR 10.4%로 2033년에는 49억 달러에 달할 것으로 예상됩니다.

알레르기 면역요법은 집먼지 진드기, 벌독, 벼 꽃가루 등 특정 알레르겐에 대한 알레르기 반응의 심각성을 감소시키는 것을 목표로 하는 알레르기 예방 치료법입니다. 이 치료법은 알레르기를 유발하는 알레르겐의 용량을 점진적으로 증가시켜 면역체계가 알레르겐에 과민반응을 일으키지 않도록 하여 알레르기 증상을 완화하는 치료법입니다. 이 치료법은 장기적인 증상 완화와 알레르기 치료에 대한 의존도를 낮출 수 있습니다.

세계 알레르기 면역요법 시장의 성장은 알레르기 비염, 천식, 음식물 알레르기 등 알레르기 질환의 유병률 증가와 알레르기 면역요법에 대한 환자와 의료진의 인식이 높아진 것이 큰 원동력이 되고 있으며, 2011년 알레르기 백서에 발표된 연구에 따르면에 따르면, 알레르기 비염의 유병률은 1%에서 18%, 피부 알레르기는 2%에서 10%, 천식은 1%에서 20%까지 다양한 인구 집단에서 발견됩니다. 또한, 알레르기 관리에 대한 효과적이고 장기적인 해결책을 찾는 환자의 증가는 알레르기 면역요법에 대한 수요를 촉진하고 시장 성장에 크게 기여하고 있습니다. 또한, 개인 맞춤형 의료에 대한 관심이 높아지면서 환자 개개인의 필요와 특정 알레르기에 대한 맞춤형 면역요법에 대한 수요가 증가하면서 시장 성장을 촉진하고 있습니다. 그러나 알레르기 면역요법과 관련된 높은 비용과 치료 부작용에 대한 우려의 증가는 시장 성장을 저해하는 주요 요인으로 작용하고 있습니다. 반면, 신흥 시장의 의료비 지출 증가는 알레르기 면역요법과 같은 첨단 치료법에 대한 접근을 용이하게 하고 있으며, 예측 기간 동안 시장 성장에 유익한 기회를 제공할 것으로 예상됩니다. 또한, 설하 면역요법의 시장 개척과 피하 면역요법의 제형 개선과 같은 면역요법 기술의 발전은 치료를 보다 효과적이고 친숙하게 만들어 시장 성장에 새로운 길을 열어줄 것으로 예상됩니다.

세계 알레르기 면역요법 시장은 유형, 용도, 유통 채널, 지역으로 분류됩니다. 유형별로는 피하 면역요법과 설하 면역요법으로 분류됩니다. 용도별로는 알레르기성 비염, 천식, 음식물 알레르기, 기타로 분류됩니다. 유통 채널별로는 병원 약국, 소매점, 온라인 약국으로 세분화됩니다. 지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 분석됩니다.

주요 조사 결과

유형별로는 피하 면역요법(SCIT) 부문이 2023년 가장 높은 시장 점유율을 차지했습니다.

용도별로는 알레르기성 비염 부문이 2033년까지 가장 높은 성장률을 보일 것으로 예상됩니다.

유통 채널별로는 병원 약국 부문이 예측 기간 동안 높은 관심을 받을 것으로 예상됩니다.

지역별로는 북미가 향후 몇 년 동안 알레르기 면역요법 시장을 주도할 것으로 예상됩니다.

본 보고서의 커스터마이징이 가능합니다(별도의 비용과 일정이 필요합니다.)

• 규제 가이드라인
• 고객의 관심사에 따른 추가 기업 개요
• 기업 개요 확대 목록
• 상환 시나리오

목차

제1장 소개

제2장 주요 요약

제3장 시장 상황

• 시장 정의와 범위
• 주요 조사 결과
  • 주요 투자 기회
  • 주요 성공 전략
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회

제4장 알레르기 면역요법 시장 : 유형별

• 시장 개요
• 피하 면역요법
• 설하 면역요법

제5장 알레르기 면역요법 시장 : 용도별

• 시장 개요
• 알레르기 비염
• 천식
• 식품 알레르기
• 기타

제6장 알레르기 면역요법 시장 : 유통 채널별

• 시장 개요
• 병원 약국
• 소매
• 온라인 약국

제7장 알레르기 면역요법 시장 : 지역별

• 시장 개요
• 북미
  • 주요 시장 동향과 기회
  • 미국의 알레르기 면역요법 시장
  • 캐나다의 알레르기 면역요법 시장
  • 멕시코의 알레르기 면역요법 시장
• 유럽
  • 주요 시장 동향과 기회
  • 프랑스의 알레르기 면역요법 시장
  • 독일의 알레르기 면역요법 시장
  • 이탈리아의 알레르기 면역요법 시장
  • 스페인의 알레르기 면역요법 시장
  • 영국의 알레르기 면역요법 시장
  • 기타 유럽의 알레르기 면역요법 시장
• 아시아태평양
  • 주요 시장 동향과 기회
  • 중국의 알레르기 면역요법 시장
  • 일본의 알레르기 면역요법 시장
  • 인도의 알레르기 면역요법 시장
  • 한국의 알레르기 면역요법 시장
  • 호주의 알레르기 면역요법 시장
  • 기타 아시아태평양의 알레르기 면역요법 시장
• 라틴아메리카, 중동 및 아프리카
  • 주요 시장 동향과 기회
  • 브라질의 알레르기 면역요법 시장
  • 남아프리카공화국의 알레르기 면역요법 시장
  • 사우디아라비아의 알레르기 면역요법 시장
  • 기타 라틴아메리카, 중동 및 아프리카의 알레르기 면역요법 시장

제8장 경쟁 상황

• 소개
• 주요 성공 전략
• 주요 10개 기업 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2023년)

제9장 기업 개요

• Torii Pharmaceutical Co., Ltd.
• Biomay AG
• ALK-Abello A/S
• Allergy Therapeutics
• Allovate, LLC
• HAL Allergy Group
• Jubliant Pharma
• Leti Pharma
• Merck KGaA
• Stallergenes Greer

ksm

영문 목차

영문목차

The allergy immunotherapy market was valued at $1.8 billion in 2023, and is projected to reach $4.9 billion by 2033, growing at a CAGR of 10.4% from 2024 to 2033.

Allergy immunotherapy is a preventative treatment for allergies that aims to mitigate the severity of allergic reactions to specific allergens such as house dust mites, bee venom, and grass pollens. This therapy involves gradual increase in administration of doses of the allergen to which an individual is allergic, thus making the immune systems less sensitive to the allergen and reducing the symptoms of allergy. The therapy can lead to long-term relief and decreased dependence on allergy medications.

The growth of the global allergy immunotherapy market is majorly driven by alarming rise in the prevalence of allergic conditions such as allergic rhinitis, asthma, and food allergies coupled with increase in awareness about allergy immunotherapy among patients and healthcare providers. Based on a 2011 study published in the White Book on Allergy, the prevalence rate of allergic rhinitis from 1% to 18%, skin allergies from 2% to 10%, and asthma ranges from 1% to 20% in various populations. Moreover, increase in preference of patients for effective and long-term solutions to allergy management fosters the demand for allergy immunotherapy, which significantly contributes toward the growth of the market. Furthermore, increase in trend toward personalized medicine is driving the demand for tailored immunotherapy treatments that address individual patient needs and specific allergies, which fosters the market growth. However, high cost of the associated with allergy immunotherapy and increase in concerns about the side effects of the treatment act as the key deterrent factors of the market. On the contrary, increase in healthcare expenditure in emerging markets is facilitating the access to advanced treatments like allergy immunotherapy, which is expected to offer remunerative opportunities for the growth of the market during the forecast period. Moreover, advancements in immunotherapy techniques, such as the development of sublingual immunotherapy and improved formulations of subcutaneous immunotherapy, are making treatments more effective and accessible, which are expected to open new avenues for the market growth.

The global allergy immunotherapy market is segmented into type, application, distribution channel, and region. On the basis of type, the market is categorized into subcutaneous immunotherapy and sublingual immunotherapy. By application, it is segregated into allergy rhinitis, asthma, food allergy, and others. Depending on distribution channel, it is fragmented into hospital pharmacies, retail, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of type, the subcutaneous immunotherapy (SCIT) segment held the highest market share in 2023.

By application, the allergic rhinitis segment is expected to exhibit highest growth rate by 2033.

Depending on distribution channel,, the hospital pharmacies segment is anticipated to gain high prominence during the forecast period.

Region wise, North America is projected to dominate the allergy immunotherapy market in the coming years.

Competition Analysis

Competitive analysis and profiles of the major players in the global allergy immunotherapy market include Torii Pharmaceutical Co., Ltd., Biomay AG, ALK-Abello A/S, Allergy Therapeutics, Allovate, LLC, HAL Allergy Group, Jubliant Pharma, Leti Pharma, Merck KGaA, and Stallergenes Greer. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and garner a strong foothold in the global market.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Expanded list for Company Profiles
• Reimbursement Scenario

Key Market Segments

By Type

• Subcutaneous Immunotherapy
• Sublingual Immunotherapy

By Application

• Allergy Rhinitis
• Asthma
• Food Allergy
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • Italy
  • Spain
  • UK
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • South Africa
  • Saudi Arabia
  • Rest of LAMEA

Key Market Players:

• Torii Pharmaceutical Co., Ltd.
• Biomay AG
• ALK-Abello A/S
• Allergy Therapeutics
• Allovate, LLC
• HAL Allergy Group
• Jubliant Pharma
• Leti Pharma
• Merck KGaA
• Stallergenes Greer

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report Description
• 1.2. Key Market Segments
• 1.3. Key Benefits
• 1.4. Research Methodology
  • 1.4.1. Primary Research
  • 1.4.2. Secondary Research
  • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

• 3.1. Market Definition and Scope
• 3.2. Key Findings
  • 3.2.1. Top Investment Pockets
  • 3.2.2. Top Winning Strategies
• 3.3. Porter's Five Forces Analysis
  • 3.3.1. Bargaining Power of Suppliers
  • 3.3.2. Threat of New Entrants
  • 3.3.3. Threat of Substitutes
  • 3.3.4. Competitive Rivalry
  • 3.3.5. Bargaining Power among Buyers
• 3.4. Market Dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: ALLERGY IMMUNOTHERAPY MARKET, BY TYPE

• 4.1. Market Overview
  • 4.1.1 Market Size and Forecast, By Type
• 4.2. Subcutaneous Immunotherapy
  • 4.2.1. Key Market Trends, Growth Factors and Opportunities
  • 4.2.2. Market Size and Forecast, By Region
  • 4.2.3. Market Share Analysis, By Country
• 4.3. Sublingual Immunotherapy
  • 4.3.1. Key Market Trends, Growth Factors and Opportunities
  • 4.3.2. Market Size and Forecast, By Region
  • 4.3.3. Market Share Analysis, By Country

CHAPTER 5: ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION

• 5.1. Market Overview
  • 5.1.1 Market Size and Forecast, By Application
• 5.2. Allergy Rhinitis
  • 5.2.1. Key Market Trends, Growth Factors and Opportunities
  • 5.2.2. Market Size and Forecast, By Region
  • 5.2.3. Market Share Analysis, By Country
• 5.3. Asthma
  • 5.3.1. Key Market Trends, Growth Factors and Opportunities
  • 5.3.2. Market Size and Forecast, By Region
  • 5.3.3. Market Share Analysis, By Country
• 5.4. Food Allergy
  • 5.4.1. Key Market Trends, Growth Factors and Opportunities
  • 5.4.2. Market Size and Forecast, By Region
  • 5.4.3. Market Share Analysis, By Country
• 5.5. Others
  • 5.5.1. Key Market Trends, Growth Factors and Opportunities
  • 5.5.2. Market Size and Forecast, By Region
  • 5.5.3. Market Share Analysis, By Country

CHAPTER 6: ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL

• 6.1. Market Overview
  • 6.1.1 Market Size and Forecast, By Distribution Channel
• 6.2. Hospital Pharmacies
  • 6.2.1. Key Market Trends, Growth Factors and Opportunities
  • 6.2.2. Market Size and Forecast, By Region
  • 6.2.3. Market Share Analysis, By Country
• 6.3. Retail
  • 6.3.1. Key Market Trends, Growth Factors and Opportunities
  • 6.3.2. Market Size and Forecast, By Region
  • 6.3.3. Market Share Analysis, By Country
• 6.4. Online Pharmacies
  • 6.4.1. Key Market Trends, Growth Factors and Opportunities
  • 6.4.2. Market Size and Forecast, By Region
  • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: ALLERGY IMMUNOTHERAPY MARKET, BY REGION

• 7.1. Market Overview
  • 7.1.1 Market Size and Forecast, By Region
• 7.2. North America
  • 7.2.1. Key Market Trends and Opportunities
  • 7.2.2. Market Size and Forecast, By Type
  • 7.2.3. Market Size and Forecast, By Application
  • 7.2.4. Market Size and Forecast, By Distribution Channel
  • 7.2.5. Market Size and Forecast, By Country
  • 7.2.6. U.S. Allergy Immunotherapy Market
    • 7.2.6.1. Market Size and Forecast, By Type
    • 7.2.6.2. Market Size and Forecast, By Application
    • 7.2.6.3. Market Size and Forecast, By Distribution Channel
  • 7.2.7. Canada Allergy Immunotherapy Market
    • 7.2.7.1. Market Size and Forecast, By Type
    • 7.2.7.2. Market Size and Forecast, By Application
    • 7.2.7.3. Market Size and Forecast, By Distribution Channel
  • 7.2.8. Mexico Allergy Immunotherapy Market
    • 7.2.8.1. Market Size and Forecast, By Type
    • 7.2.8.2. Market Size and Forecast, By Application
    • 7.2.8.3. Market Size and Forecast, By Distribution Channel
• 7.3. Europe
  • 7.3.1. Key Market Trends and Opportunities
  • 7.3.2. Market Size and Forecast, By Type
  • 7.3.3. Market Size and Forecast, By Application
  • 7.3.4. Market Size and Forecast, By Distribution Channel
  • 7.3.5. Market Size and Forecast, By Country
  • 7.3.6. France Allergy Immunotherapy Market
    • 7.3.6.1. Market Size and Forecast, By Type
    • 7.3.6.2. Market Size and Forecast, By Application
    • 7.3.6.3. Market Size and Forecast, By Distribution Channel
  • 7.3.7. Germany Allergy Immunotherapy Market
    • 7.3.7.1. Market Size and Forecast, By Type
    • 7.3.7.2. Market Size and Forecast, By Application
    • 7.3.7.3. Market Size and Forecast, By Distribution Channel
  • 7.3.8. Italy Allergy Immunotherapy Market
    • 7.3.8.1. Market Size and Forecast, By Type
    • 7.3.8.2. Market Size and Forecast, By Application
    • 7.3.8.3. Market Size and Forecast, By Distribution Channel
  • 7.3.9. Spain Allergy Immunotherapy Market
    • 7.3.9.1. Market Size and Forecast, By Type
    • 7.3.9.2. Market Size and Forecast, By Application
    • 7.3.9.3. Market Size and Forecast, By Distribution Channel
  • 7.3.10. UK Allergy Immunotherapy Market
    • 7.3.10.1. Market Size and Forecast, By Type
    • 7.3.10.2. Market Size and Forecast, By Application
    • 7.3.10.3. Market Size and Forecast, By Distribution Channel
  • 7.3.11. Rest of Europe Allergy Immunotherapy Market
    • 7.3.11.1. Market Size and Forecast, By Type
    • 7.3.11.2. Market Size and Forecast, By Application
    • 7.3.11.3. Market Size and Forecast, By Distribution Channel
• 7.4. Asia-Pacific
  • 7.4.1. Key Market Trends and Opportunities
  • 7.4.2. Market Size and Forecast, By Type
  • 7.4.3. Market Size and Forecast, By Application
  • 7.4.4. Market Size and Forecast, By Distribution Channel
  • 7.4.5. Market Size and Forecast, By Country
  • 7.4.6. China Allergy Immunotherapy Market
    • 7.4.6.1. Market Size and Forecast, By Type
    • 7.4.6.2. Market Size and Forecast, By Application
    • 7.4.6.3. Market Size and Forecast, By Distribution Channel
  • 7.4.7. Japan Allergy Immunotherapy Market
    • 7.4.7.1. Market Size and Forecast, By Type
    • 7.4.7.2. Market Size and Forecast, By Application
    • 7.4.7.3. Market Size and Forecast, By Distribution Channel
  • 7.4.8. India Allergy Immunotherapy Market
    • 7.4.8.1. Market Size and Forecast, By Type
    • 7.4.8.2. Market Size and Forecast, By Application
    • 7.4.8.3. Market Size and Forecast, By Distribution Channel
  • 7.4.9. South Korea Allergy Immunotherapy Market
    • 7.4.9.1. Market Size and Forecast, By Type
    • 7.4.9.2. Market Size and Forecast, By Application
    • 7.4.9.3. Market Size and Forecast, By Distribution Channel
  • 7.4.10. Australia Allergy Immunotherapy Market
    • 7.4.10.1. Market Size and Forecast, By Type
    • 7.4.10.2. Market Size and Forecast, By Application
    • 7.4.10.3. Market Size and Forecast, By Distribution Channel
  • 7.4.11. Rest of Asia-Pacific Allergy Immunotherapy Market
    • 7.4.11.1. Market Size and Forecast, By Type
    • 7.4.11.2. Market Size and Forecast, By Application
    • 7.4.11.3. Market Size and Forecast, By Distribution Channel
• 7.5. LAMEA
  • 7.5.1. Key Market Trends and Opportunities
  • 7.5.2. Market Size and Forecast, By Type
  • 7.5.3. Market Size and Forecast, By Application
  • 7.5.4. Market Size and Forecast, By Distribution Channel
  • 7.5.5. Market Size and Forecast, By Country
  • 7.5.6. Brazil Allergy Immunotherapy Market
    • 7.5.6.1. Market Size and Forecast, By Type
    • 7.5.6.2. Market Size and Forecast, By Application
    • 7.5.6.3. Market Size and Forecast, By Distribution Channel
  • 7.5.7. South Africa Allergy Immunotherapy Market
    • 7.5.7.1. Market Size and Forecast, By Type
    • 7.5.7.2. Market Size and Forecast, By Application
    • 7.5.7.3. Market Size and Forecast, By Distribution Channel
  • 7.5.8. Saudi Arabia Allergy Immunotherapy Market
    • 7.5.8.1. Market Size and Forecast, By Type
    • 7.5.8.2. Market Size and Forecast, By Application
    • 7.5.8.3. Market Size and Forecast, By Distribution Channel
  • 7.5.9. Rest of LAMEA Allergy Immunotherapy Market
    • 7.5.9.1. Market Size and Forecast, By Type
    • 7.5.9.2. Market Size and Forecast, By Application
    • 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top Winning Strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

• 9.1. Torii Pharmaceutical Co., Ltd.
  • 9.1.1. Company Overview
  • 9.1.2. Key Executives
  • 9.1.3. Company Snapshot
  • 9.1.4. Operating Business Segments
  • 9.1.5. Product Portfolio
  • 9.1.6. Business Performance
  • 9.1.7. Key Strategic Moves and Developments
• 9.2. Biomay AG
  • 9.2.1. Company Overview
  • 9.2.2. Key Executives
  • 9.2.3. Company Snapshot
  • 9.2.4. Operating Business Segments
  • 9.2.5. Product Portfolio
  • 9.2.6. Business Performance
  • 9.2.7. Key Strategic Moves and Developments
• 9.3. ALK-Abello A/S
  • 9.3.1. Company Overview
  • 9.3.2. Key Executives
  • 9.3.3. Company Snapshot
  • 9.3.4. Operating Business Segments
  • 9.3.5. Product Portfolio
  • 9.3.6. Business Performance
  • 9.3.7. Key Strategic Moves and Developments
• 9.4. Allergy Therapeutics
  • 9.4.1. Company Overview
  • 9.4.2. Key Executives
  • 9.4.3. Company Snapshot
  • 9.4.4. Operating Business Segments
  • 9.4.5. Product Portfolio
  • 9.4.6. Business Performance
  • 9.4.7. Key Strategic Moves and Developments
• 9.5. Allovate, LLC
  • 9.5.1. Company Overview
  • 9.5.2. Key Executives
  • 9.5.3. Company Snapshot
  • 9.5.4. Operating Business Segments
  • 9.5.5. Product Portfolio
  • 9.5.6. Business Performance
  • 9.5.7. Key Strategic Moves and Developments
• 9.6. HAL Allergy Group
  • 9.6.1. Company Overview
  • 9.6.2. Key Executives
  • 9.6.3. Company Snapshot
  • 9.6.4. Operating Business Segments
  • 9.6.5. Product Portfolio
  • 9.6.6. Business Performance
  • 9.6.7. Key Strategic Moves and Developments
• 9.7. Jubliant Pharma
  • 9.7.1. Company Overview
  • 9.7.2. Key Executives
  • 9.7.3. Company Snapshot
  • 9.7.4. Operating Business Segments
  • 9.7.5. Product Portfolio
  • 9.7.6. Business Performance
  • 9.7.7. Key Strategic Moves and Developments
• 9.8. Leti Pharma
  • 9.8.1. Company Overview
  • 9.8.2. Key Executives
  • 9.8.3. Company Snapshot
  • 9.8.4. Operating Business Segments
  • 9.8.5. Product Portfolio
  • 9.8.6. Business Performance
  • 9.8.7. Key Strategic Moves and Developments
• 9.9. Merck KGaA
  • 9.9.1. Company Overview
  • 9.9.2. Key Executives
  • 9.9.3. Company Snapshot
  • 9.9.4. Operating Business Segments
  • 9.9.5. Product Portfolio
  • 9.9.6. Business Performance
  • 9.9.7. Key Strategic Moves and Developments
• 9.10. Stallergenes Greer
  • 9.10.1. Company Overview
  • 9.10.2. Key Executives
  • 9.10.3. Company Snapshot
  • 9.10.4. Operating Business Segments
  • 9.10.5. Product Portfolio
  • 9.10.6. Business Performance
  • 9.10.7. Key Strategic Moves and Developments

관련자료